[Studies on lung targeted niosomes of XXXX ].

@entity19 @entity3003 @entity5 @entity2 @entity24896
AIM: To improve the treatment efficacy and reduce the side effect of @entity3003 ( @entity24896 ), the antitumor drug was incorporated into niosomes (NS). METHODS: Lung targeted niosomes of @entity24896 ( @entity24896 ) were prepared by the method of hand shaking. The ultraviolet absorption spectrophotometric method was used for the determination of @entity24896 . The method of dynamic dialysis was used for in vitro release of @entity24896 from @entity24896 . The S-180 @entity2 models were established by i.v. @entity5 cells in @entity19 . The number of pulmonary nodules was examined for evaluating the therapeutic efficacy. RESULTS: The data showed that the mean diameter of @entity24896 was 3.72 microns, with a span of 0.66. The entrapment ratio of @entity24896 in @entity24896 was 29.2% and the @entity24896 were stable for three months stored at 3 degrees C-5 degrees C, 15 degrees C-25 degrees C or 37 degrees C (relative humidity 75%). The release profile in vitro could be described by a biexpotential equation. The calculated values of the three targeting parameters indicated that @entity24896 showed good targeting efficiency. The results of therapeutic trials showed that the antitumor effects were significantly increased by injection of @entity24896 compared with @entity24896 in the treatment of @entity19 with @entity2 . CONCLUSION: The results indicated that @entity24896 have good targeting efficiency in vivo, and the biodegradable @entity24896 may decrease the side effects of @entity3003 and improve its therapeutic efficacy.
